CARLSBAD, Calif., April 3 /PRNewswire-FirstCall/ --
The Immune Response Corporation (Nasdaq: IMNR) is pleased to announce that at
the Special Meeting of Stockholders held on April 2, 2002 at the Company's
offices, the stockholders of the Company approved the November 2001 financing
and subsequent financing proposal.
The Immune Response Corporation is a biopharmaceutical company based in
Carlsbad, California, developing immune-based therapies to induce specific
immune responses for the treatment of HIV, autoimmune diseases and cancer. In
addition, the Company is developing a targeted, non-viral delivery technology
for gene therapy, which is designed to enable the delivery of genes directly
to the liver via intravenous injection.
NOTE: Company information can also be located on the Internet Web Site:
http://www.imnr.com .
This news release contains forward-looking statements. Actual results
could vary materially from those expected due to a variety of risk factors,
including the uncertainty of successful completion of clinical trials, and
those risks set forth from time to time in The Immune Response Corporation's
SEC filings, including but not limited to its report on Form 10-K for the year
ended December 31, 2001. The Company undertakes no obligation to publicly
release the result of any revisions to these forward-looking statements, which
may be made to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events.
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
Company News On-Call:
http://www.prnewswire.com/comp/434675.html
CONTACT:
Howard Sampson, Vice President, Finance,
Chief Financial Officer and Treasurer of The Immune Response
Corporation, +1-760-431-7080
|
